Document Detail


Comparison of ras-responsive gene enhancers in pancreatic tumor cells that express either wild-type or mutant K-ras.
MedLine Citation:
PMID:  19254697     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There is a pressing need for new therapies to treat pancreatic cancer. In principle, this could be achieved by taking advantage of signaling pathways that are active in tumor, but not normal, cells. The work described in this study set out to determine whether the activities of three enhancers, which have been reported to be highly responsive to activated ras, differ in pancreatic tumor cells that express wild-type versus constitutively active mutant forms of K-ras. Surprisingly, the three enhancers are active in four different pancreatic tumor cell lines that express either normal K-ras gene or mutant K-ras. Moreover, reducing the concentration of serum in the growth medium from 10% to 0.5% had relatively little effect on the strength of any of the enhancers, although it drastically affected cell growth. Importantly, our studies also indicate that MEK is active in pancreatic tumor cells that possess wild-type as well as mutant K-ras, even when cultured in medium that severely limits cell growth. These findings support the hypothesis that the Ras/Raf/Mek/Erk pathway may be constitutively active even in pancreatic tumor cells that express wild-type K-ras.
Authors:
Phillip J Wilder; Harini Chakravarthy; Michael A Hollingsworth; Angie Rizzino
Related Documents :
10579847 - Discovery of a series of cyclohexylethylamine-containing protein farnesyltransferase in...
15284217 - Loss of metal transcription factor-1 suppresses tumor growth through enhanced matrix de...
15607957 - Oncogene addiction: sometimes a temporary slavery.
12118537 - Relationship between intrinsic radiation sensitivity and metastatic potential.
12242297 - Pax3-fkhr knock-in mice show developmental aberrations but do not develop tumors.
16340727 - In-vivo visualization of radiation-induced apoptosis using (125)i-annexin v.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2009-02-28
Journal Detail:
Title:  Biochemical and biophysical research communications     Volume:  381     ISSN:  1090-2104     ISO Abbreviation:  Biochem. Biophys. Res. Commun.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-03-30     Completed Date:  2009-04-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372516     Medline TA:  Biochem Biophys Res Commun     Country:  United States    
Other Details:
Languages:  eng     Pagination:  706-11     Citation Subset:  IM    
Affiliation:
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, 68198-6805, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Culture Media
Enhancer Elements, Genetic / genetics*
Humans
Mutation
Pancreatic Neoplasms / genetics*
Proto-Oncogene Proteins p21(ras) / genetics*
Signal Transduction
ras Proteins / metabolism*
Grant Support
ID/Acronym/Agency:
CA36727/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Culture Media; EC 3.6.5.2/Proto-Oncogene Proteins p21(ras); EC 3.6.5.2/ras Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mutation in gap and tight junctions in patients with non-syndromic hearing loss.
Next Document:  Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway.